- Home
- ENGN vs SGHT Comparison
ENGN vs SGHT Comparison
Compare ENGN & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- SGHT
- Stock Information
- Founded
- ENGN 1999
- SGHT 2011
- Country
- ENGN Canada
- SGHT United States
- Employees
- ENGN N/A
- SGHT N/A
- Industry
- ENGN
- SGHT Medical Specialities
- Sector
- ENGN
- SGHT Health Care
- Exchange
- ENGN Nasdaq
- SGHT Nasdaq
- Market Cap
- ENGN 293.1M
- SGHT 304.4M
- IPO Year
- ENGN N/A
- SGHT 2021
- Fundamental
- Price
- ENGN $6.08
- SGHT $3.58
- Analyst Decision
- ENGN Strong Buy
- SGHT Buy
- Analyst Count
- ENGN 8
- SGHT 7
- Target Price
- ENGN $30.38
- SGHT $6.27
- AVG Volume (30 Days)
- ENGN 188.1K
- SGHT 217.8K
- Earning Date
- ENGN 01-27-2025
- SGHT 11-07-2024
- Dividend Yield
- ENGN N/A
- SGHT N/A
- EPS Growth
- ENGN N/A
- SGHT N/A
- EPS
- ENGN N/A
- SGHT N/A
- Revenue
- ENGN N/A
- SGHT $79,543,000.00
- Revenue This Year
- ENGN N/A
- SGHT $2.18
- Revenue Next Year
- ENGN N/A
- SGHT $8.14
- P/E Ratio
- ENGN N/A
- SGHT N/A
- Revenue Growth
- ENGN N/A
- SGHT N/A
- 52 Week Low
- ENGN $4.42
- SGHT $3.12
- 52 Week High
- ENGN $18.40
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- ENGN 26.04
- SGHT 33.92
- Support Level
- ENGN $8.00
- SGHT $3.65
- Resistance Level
- ENGN $7.97
- SGHT $4.04
- Average True Range (ATR)
- ENGN 0.72
- SGHT 0.21
- MACD
- ENGN -0.24
- SGHT 0.04
- Stochastic Oscillator
- ENGN 2.22
- SGHT 2.25
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.